Alternative therapy interaction with warfarin: what doctors should know
Abstract
Warfarin effectiveness and safety is substantially affected by concurrent therapy. This paper reviews the main mechanisms of warfarin interactions with other agents, which underlie adverse effect development: platelet dysfunction, gastro-intestinal effects, suppressed intestinal synthesis of vitamin K, disturbed warfarin metabolism, or disrupted vitamin K cycle. The main medication groups, affecting warfarin effectiveness and safety, are presented. The effects of foods, supplements, and herbal medications on anticoagulant effect of warfarin are discussed.
About the Authors
T. B. Kozlova
I.M. Sechenov Moscow Medical Academy. Moscow
Russian Federation
Russian Federation
T. V. Taratuta
I.M. Sechenov Moscow Medical Academy. Moscow
Russian Federation
Russian Federation
M. B. Aksenova
I.M. Sechenov Moscow Medical Academy. Moscow
Russian Federation
Russian Federation
T. V. Khlevchuk
I.M. Sechenov Moscow Medical Academy. Moscow
Russian Federation
Russian Federation
References
1. Anthony M, Romero K, Malone DC, et al. Warfarin Interactions With Substances Listed in Drug Information Compendia and in the FDA-Approved Label for Warfarin Sodium. Clin pharmacy Ther 2009; 86: 425—9.
2. Chagan L, Bernstein D, Cheng JW, et al. Use of biological based therapy in patients with cardiovascular diseases in a universityhospital in New York City. BMC Complement Altern Med 2005; 5: 4—13.
3. Conly JM, Stein K, Worobetz L, et al. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol 1994; 89: 915—23.
4. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990—1997: results of a follow-up national survey. JAMA 1998; 280: 1569—75.
5. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007; 23: 134—41.
6. Foti RS, Wahlstrom JL, Wienkers LC. The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Disp 2007; 35: 185—8.
7. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45: 127—32.
8. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095—106.
9. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005; 65(9): 1239—82.
10. Joshi BS, Kaul PN. Alternative medicine: herbal drugs and their critical appraisal—part I. Prog Drug Res 2001; 56: 1—76.
11. Lumb AB. Effect of dried ginger on human platelet function. Thromb Haemost 1994; 71: 110—1.
12. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91: 119—28.
13. Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for health-care professionals. London: Pharmaceutical Press 1996.
14. Nutescu EA, Shapiro NL, Ibrahim S, et al. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006; 5: 433—51.
15. Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm 2001; 58: 2076—80.
16. Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. Am J Health Syst Pharm 1998; 55: 1581—3.
17. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587—603.
18. Thijssen HH, Soute BA, Vervoort LM, et al. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92: 797—802.
19. Wittkowsky Ann K. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J Thromb Thrombolysis 2008; 25: 72—7.
20. Wood MJ, Stewart RL, Merry H, et al. Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J 2003; 145: 806—12.
21. Zhaoping LI, Seerman NP, Carpenter CL, et al. Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 2006; 106: 2057—61.
Review
For citations:
Kozlova T.B., Taratuta T.V., Aksenova M.B., Khlevchuk T.V. Alternative therapy interaction with warfarin: what doctors should know. Cardiovascular Therapy and Prevention. 2010;9(3):106-110. (In Russ.)
Views:
612
Email this article 
